SubHero Banner

Vascepa® (icosapent ethyl) – New indication

December 13, 2019, - The FDA announced the approval of Amarin Pharma’s Vascepa (icosapent ethyl), as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and: established cardiovascular (CV) disease or diabetes mellitus and 2 or more additional risk factors for CV disease.

Download PDF